Bevacizumab (Bev)-based therapy for patients (pts) with colorectal cancer (CRC): McGill University and Segal Cancer Centre experience.
D. W. Wasserman
No relevant relationships to disclose
N. Bouganim
No relevant relationships to disclose
G. Batist
No relevant relationships to disclose
P. Metrakos
No relevant relationships to disclose
P. Chaudhury
No relevant relationships to disclose
M. Hassanain
No relevant relationships to disclose
P. Kavan
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche